Diplomat Pharmacy,Inc. (NYSE:DPLO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Restricted Stock Unit Awards

On April4, 2017, the Board of Directors of Diplomat Pharmacy,Inc.
(the Company) approved a form of Restricted Stock Unit Award
Agreement (Time-Based) (the RSU Award Agreement) for restricted
stock units (RSUs) to be issued from time to time under the
Companys 2014 Omnibus Incentive Plan. Under the terms of the RSU
Award Agreement, the Company may issue the right to receive, upon
vesting and the satisfaction of any required tax withholding
obligation, shares of common stock, no par value, of the Company
(Common Stock), which will become vested as set forth in the
applicable award on the basis of one share of Common Stock for
each RSU, provided that the grantee has remained continuously
employed by the Company from the grant date to such vesting date.
The Formof RSU Award Agreement (Time-Based) is attached hereto as
Exhibit10.1 and is incorporated herein by reference.

On April4, 2017, the Companys Board of Directors approved the
issuance of time-based RSU awards to certain employees, including
two of the Companys executive officers in the following amounts:
Paul Urick, its President, 7,253 RSUs, and Gary Rice, its
Executive Vice President of Operations, 4,587 RSUs.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits

About Diplomat Pharmacy, Inc. (NYSE:DPLO)

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Recent Trading Information

Diplomat Pharmacy, Inc. (NYSE:DPLO) closed its last trading session up +0.12 at 14.38 with 686,837 shares trading hands.